Product NDC: | 61703-343 |
Proprietary Name: | Mitoxantrone |
Non Proprietary Name: | MITOXANTRONE HYDROCHLORIDE |
Active Ingredient(s): | 2 mg/mL & nbsp; MITOXANTRONE HYDROCHLORIDE |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION, CONCENTRATE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 61703-343 |
Labeler Name: | Hospira Worldwide, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA076871 |
Marketing Category: | ANDA |
Start Marketing Date: | 20060411 |
Package NDC: | 61703-343-66 |
Package Description: | 15 mL in 1 VIAL, MULTI-DOSE (61703-343-66) |
NDC Code | 61703-343-66 |
Proprietary Name | Mitoxantrone |
Package Description | 15 mL in 1 VIAL, MULTI-DOSE (61703-343-66) |
Product NDC | 61703-343 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | MITOXANTRONE HYDROCHLORIDE |
Dosage Form Name | INJECTION, SOLUTION, CONCENTRATE |
Route Name | INTRAVENOUS |
Start Marketing Date | 20060411 |
Marketing Category Name | ANDA |
Labeler Name | Hospira Worldwide, Inc. |
Substance Name | MITOXANTRONE HYDROCHLORIDE |
Strength Number | 2 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Topoisomerase Inhibitor [EPC],Topoisomerase Inhibitors [MoA] |